Reston – March 6, 2024 – Cooley advised Adaptive Phage Therapeutics (APT), a US-based, privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, on its definitive merger agreement with BiomX (NYSE: PHGE), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria. Lawyers Christian Plaza, Matthew Silverman, Brian Leaf, Matthew Schwee, Joyce Li and Rasha Printz led the Cooley team advising APT.
Immediately after the effective date of the merger, BiomX will own approximately 55%, and the former stockholders of APT will own approximately 45%, of the consolidated entity of BiomX and APT. The merger is expected to close within the next 30 days, subject to the satisfaction of the closing conditions described in the definitive merger agreement.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.